AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC

Posted inBiotechnology

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug candidates.